Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$29.98−2.34 (-7.24%)
Close on Nov 17, 2026Market cap $352.37MP/E –Yield –
Surrozen operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Surrozen's operating cash flow for the twelve months ending Jun 30, 2026 was -$34.76M. For fiscal 2025 it was -$30.24M. The highest annual figure on record is -$17.63M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$30.24M | – |
| FY2024 | Dec 31, 2024 | -$17.63M | – |
| FY2023 | Dec 31, 2023 | -$40.36M | – |
| FY2022 | Dec 31, 2022 | -$44.15M | – |
| FY2021 | Dec 31, 2021 | -$48.81M | – |
| FY2020 | Dec 31, 2020 | -$29.10M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.81M | -267.0% |
| Q3 FY2025 | Sep 30, 2025 | -$9.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.28M | – |
| Q4 FY2024 | Dec 31, 2024 | $3.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.13M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.17M | – |
| Q4 FY2022 | Dec 31, 2022 | -$205.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.33M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.34M | – |
See a number that looks wrong?